NCT02556801View on ClinicalTrials.gov

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

PHASE2CompletedINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Allergic RhinitisAllergic Rhinoconjunctivitis

Interventions

BIOLOGICAL

SUBLIVAC FIX Phleum Prat.

sublingual daily administration

Trial Locations (1)

ON L4W 1A4

Inflamax Research Inc., Mississauga

Sponsors

Lead Sponsor

All Listed Sponsors

lead

HAL Allergy

INDUSTRY